{"product_id":"modern-drug-synthesis-hardback-9780470525838","title":"Modern Drug Synthesis (Hardback) 9780470525838","description":"\u003cfont face=\"Georgia\"\u003e\r\n\u003cp\u003e\u003cfont size=\"6\"\u003eModern Drug Synthesis\u003c\/font\u003e\u003cbr\u003e\r\n\r\n\r\n\r\n\r\n\r\n\u003c\/p\u003e\n\u003cp\u003e\u003cfont size=\"4\"\u003eJie Jack Li (Edited by), JJ Li (Author), Douglas S. Johnson (Edited by)\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e9780470525838, Wiley\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eHardback, published 27 August 2010\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003e384 pages\u003cbr\u003e25.6 x 18.3 x 2.8 cm, 0.839 kg\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\r\n\u003cp align=\"justify\"\u003e\u003cem\u003e\u003cfont size=\"3\"\u003e\"All chapters are very well written, and the used schemes and tables are conveniently arranged. The information and explanations given are strengthened by well-chosen examples and so the reader can easily follow the discussion. The comprehensive referenced literature placed at the end of each chapter enables further reading, and a detailed keyword index in combination with a logically structured Table of Content allows fast access to the topic of interest.\" (\u003ci\u003eChemMedChem\u003c\/i\u003e, 2010)\u003cbr\u003e \u003cbr\u003e\u003c\/font\u003e\u003c\/em\u003e\u003c\/p\u003e\r\n\r\n\u003cp align=\"justify\"\u003e\u003cstrong\u003e\u003cfont size=\"3\"\u003eFollowing \u003ci\u003eContemporary Drug Synthesis and The Art of Drug Synthesis\u003c\/i\u003e (Wiley, 2004 and 2007), two well-received works, is this new book that demystifies the process of modern drug discovery for practitioners and students. An enhanced introduction covers areas such as background, pharmacology, SAR, PK\/PD, efficacy, and safety. Focusing on the advantages of process synthesis versus the discovery synthetic route, Modern Drug Synthesis features authoritative coverage by distinguished editors and authors (some chapter authors are the actual inventor of the drug) of twenty different drug molecules.\u003c\/font\u003e\u003c\/strong\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003ePreface xi \u003cp\u003eContributors xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eI. Infectious Diseases 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 1. Raltegravir (Isentress), The First-in-class HIV-1 Integrase Inhibitor 3\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJulianne A. Hunt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 Background 3\u003c\/p\u003e \u003cp\u003e1.2 Pharmacology 5\u003c\/p\u003e \u003cp\u003e1.3 Structure-Activity Relationship (SAR) 6\u003c\/p\u003e \u003cp\u003e1.4 Pharmacokinetics and Drug Metabolism 8\u003c\/p\u003e \u003cp\u003e1.5 Efficacy and Safety 9\u003c\/p\u003e \u003cp\u003e1.6 Syntheses 10\u003c\/p\u003e \u003cp\u003e1.7 References 13\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 2. Maraviroc (Selzentry), The First-in-class CCR5 Antagonist for the Treatment of HIV 17\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDavid Price\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Background 17\u003c\/p\u003e \u003cp\u003e2.2 Structure-Activity Relationship (SAR) 19\u003c\/p\u003e \u003cp\u003e2.3 Pharmacokinetics and Safety 21\u003c\/p\u003e \u003cp\u003e2.4 Syntheses 22\u003c\/p\u003e \u003cp\u003e2.5 References 27\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 3. Darunavir (Prezista), A HIV-1 Protease Inhibitor for Treatment of Multidrug Resistant HIV 29\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eArun K. Ghosh and Cuthbert D. Martyr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 Background 29\u003c\/p\u003e \u003cp\u003e3.2 Pharmacology 32\u003c\/p\u003e \u003cp\u003e3.3 Structure-Activity Relationship (SAR) 32\u003c\/p\u003e \u003cp\u003e3.4 Pharmacokinetics and Drug Metabolism 33\u003c\/p\u003e \u003cp\u003e3.5 Efficacy and Safety 33\u003c\/p\u003e \u003cp\u003e3.6 Syntheses 34\u003c\/p\u003e \u003cp\u003e3.7 References 42\u003c\/p\u003e \u003cp\u003e\u003cb\u003eII. Cancer 45\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 4. Decitabine (Dacogen), A DNA Methyltransferase Inhibitor for Cancer 47\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJennifer A. Van Camp\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 Background 47\u003c\/p\u003e \u003cp\u003e4.2 Pharmacology 49\u003c\/p\u003e \u003cp\u003e4.3 Structure-Activity Relationship (SAR) 49\u003c\/p\u003e \u003cp\u003e4.4 Pharmacokinetics and Drug Metabolism 50\u003c\/p\u003e \u003cp\u003e4.5 Efficacy and Safety 50\u003c\/p\u003e \u003cp\u003e4.6 Syntheses 51\u003c\/p\u003e \u003cp\u003e4.7 References 54\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 5. Capecitabine (Xeloda), An Oral Chemotherapy Agent 57\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eR. Jason Herr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Background 57\u003c\/p\u003e \u003cp\u003e5.2 Pharmacology 60\u003c\/p\u003e \u003cp\u003e5.3 Structure-Activity Relationship (SAR) 62\u003c\/p\u003e \u003cp\u003e5.4 Pharmacokinetics and Efficacy 63\u003c\/p\u003e \u003cp\u003e5.5 Syntheses 64\u003c\/p\u003e \u003cp\u003e5.6 References 70\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 6. Sorafenib (Nexavar), A Multi-kinase Inhibitor for Advanced Renal Cell Carcinoma and Unresectable Hepatocellular Carcinoma 73\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eShuanghua Hu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Background 73\u003c\/p\u003e \u003cp\u003e6.2 Pharmacology 75\u003c\/p\u003e \u003cp\u003e6.3 Structure-Activity Relationship (SAR) 77\u003c\/p\u003e \u003cp\u003e6.4 Pharmacokinetics and Drug Metabolism 78\u003c\/p\u003e \u003cp\u003e6.5 Efficacy and Safety 78\u003c\/p\u003e \u003cp\u003e6.6 Syntheses 79\u003c\/p\u003e \u003cp\u003e6.7 References 84\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 7. Sunitinib (Sutent), An Angiogenesis Inhibitor 87\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMartin Pettersson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 Background 87\u003c\/p\u003e \u003cp\u003e7.2 Discovery and Development 89\u003c\/p\u003e \u003cp\u003e7.3 Syntheses 91\u003c\/p\u003e \u003cp\u003e7.3.1 Discovery Route 91\u003c\/p\u003e \u003cp\u003e7.3.2 Process Route 92\u003c\/p\u003e \u003cp\u003e7.4 References 97\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 8. Bortezomib (Velcade), A First-in-class Proteasome Inhibitor 99\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eBenjamin S. Greener and David S. Millan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8.1 Background 99\u003c\/p\u003e \u003cp\u003e8.2 Pharmacology 101\u003c\/p\u003e \u003cp\u003e8.3 Structure-Activity Relationship (SAR) 102\u003c\/p\u003e \u003cp\u003e8.4 Pharmacokinetics and Drug Metabolism 104\u003c\/p\u003e \u003cp\u003e8.5 Efficacy and Safety 104\u003c\/p\u003e \u003cp\u003e8.6 Syntheses 105\u003c\/p\u003e \u003cp\u003e8.7 References 109\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 9. Pazopanib (Votrient), A VEGFR Tyrosine Kinase Inhibitor for Cancer 111\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJi Zhang and Jie Jack Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9.1 Background 111\u003c\/p\u003e \u003cp\u003e9.2 Pharmacology 113\u003c\/p\u003e \u003cp\u003e9.3 Structure?Activity Relationship (SAR) 114\u003c\/p\u003e \u003cp\u003e9.4 Pharmacokinetics and Drug Metabolism 117\u003c\/p\u003e \u003cp\u003e9.5 Efficacy and Safety 118\u003c\/p\u003e \u003cp\u003e9.6 Syntheses 118\u003c\/p\u003e \u003cp\u003e9.7 Other VEGFR Inhibitors in Development: Vandetanib and Cediranib 120\u003c\/p\u003e \u003cp\u003e9.8 References 121\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIII. Cardiovascular and Metabolic Diseases 123\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 10. Sitagliptin (Januvia), A Treatment for Type 2 Diabetes 125\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eScott D. Edmondson, Feng Xu, and Joseph D. Armstrong III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10.1 Background 125\u003c\/p\u003e \u003cp\u003e10.2 Pharmacology 126\u003c\/p\u003e \u003cp\u003e10.3 Structure-Activity Relationship (SAR) 127\u003c\/p\u003e \u003cp\u003e10.4 Pharmacokinetics and Drug Metabolism 128\u003c\/p\u003e \u003cp\u003e10.5 Efficacy and Safety 129\u003c\/p\u003e \u003cp\u003e10.6 Syntheses 130\u003c\/p\u003e \u003cp\u003e10.7 References 138\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 11. Aliskiren (Tekturna), The First-in-class Renin Inhibitor for Hypertension 141\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eVictor J. Cee\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11.1 Background 141\u003c\/p\u003e \u003cp\u003e11.2 Pharmacology 144\u003c\/p\u003e \u003cp\u003e11.3 Structure-Activity Relationship (SAR) n145\u003c\/p\u003e \u003cp\u003e11.4 Pharmacokinetics and Drug Metabolism 146\u003c\/p\u003e \u003cp\u003e11.5 Efficacy and Safety 147\u003c\/p\u003e \u003cp\u003e11.6 Syntheses 148\u003c\/p\u003e \u003cp\u003e11.7 References 156\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 12. Vernakalant (Kynapid), An Investigational Drug for the Treatment of Atrial Fibrillation 159\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDavid L. Gray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12.1 Background 159\u003c\/p\u003e \u003cp\u003e12.2 Pharmacology 163\u003c\/p\u003e \u003cp\u003e12.3 Structure-Activity Relationship (SAR) 163\u003c\/p\u003e \u003cp\u003e12.4 Pharmacokinetics and Drug Metabolism 164\u003c\/p\u003e \u003cp\u003e12.5 Efficacy and Safety 165\u003c\/p\u003e \u003cp\u003e12.6 Syntheses 166\u003c\/p\u003e \u003cp\u003e12.7 References 171\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 13. Conivaptan (Vaprisol), Vasopressin V1a and V2 Antagonist for Hyponatremia 175\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eBrian A. Lanman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Background 175\u003c\/p\u003e \u003cp\u003e13.2 Pharmacology 177\u003c\/p\u003e \u003cp\u003e13.3 Structure-Activity Relationship (SAR) 179\u003c\/p\u003e \u003cp\u003e13.4 Pharmacokinetics and Drug Metabolism 181\u003c\/p\u003e \u003cp\u003e13.5 Efficacy and Safety 182\u003c\/p\u003e \u003cp\u003e13.6 Syntheses 183\u003c\/p\u003e \u003cp\u003e13.7 References 189\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 14. Rivaroxaban (Xarelto), A Factor Xa Inhibitor for the Treatment of Thrombotic Events 191\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJi Zhang and Jason Crawford\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14.1 Background 191\u003c\/p\u003e \u003cp\u003e14.2 Pharmacology 193\u003c\/p\u003e \u003cp\u003e14.3 Structure?Activity Relationship (SAR) 194\u003c\/p\u003e \u003cp\u003e14.4 Pharmacokinetics and Drug Metabolism 196\u003c\/p\u003e \u003cp\u003e14.5 Efficacy and Safety 197\u003c\/p\u003e \u003cp\u003e14.6 Syntheses 198\u003c\/p\u003e \u003cp\u003e14.7 Compounds in Development: Apixaban and Otamixaban 203\u003c\/p\u003e \u003cp\u003e14.8 References 204\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 15. Endothelin Antagonists for the Treatment of Pulmonary Arterial Hypertension 207\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eDavid Edmonds\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15.1 Background 208\u003c\/p\u003e \u003cp\u003e15.2 Treatment of PAH 209\u003c\/p\u003e \u003cp\u003e15.3 Endothelin Antagonists 211\u003c\/p\u003e \u003cp\u003e15.4 Synthesis of Bosentan 215\u003c\/p\u003e \u003cp\u003e15.5 Synthesis of Sitaxsentan 217\u003c\/p\u003e \u003cp\u003e15.6 Synthesis of Ambrisentan 219\u003c\/p\u003e \u003cp\u003e15.7 Conclusion 221\u003c\/p\u003e \u003cp\u003e15.8 References 221\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIV. Central Nervous System Diseases 225\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 16. Varenicline (Chantix), An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation 227\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJotham W. Coe, Frank R. Busch and Robert A. Singer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16.1 Background 227\u003c\/p\u003e \u003cp\u003e16.2 Discovery Chemistry Program 229\u003c\/p\u003e \u003cp\u003e16.3 Pharmacology 231\u003c\/p\u003e \u003cp\u003e16.4 Pharmacokinetics and Drug Metabolism 231\u003c\/p\u003e \u003cp\u003e16.5 Efficacy and Safety 232\u003c\/p\u003e \u003cp\u003e16.6 Syntheses 232\u003c\/p\u003e \u003cp\u003e16.7 References 244\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 17. Donepezil, Rivastigmine, Galantamine: Cholinesterase Inhibitors for Alzheimer's Disease 249\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSubas Sakya and Kapil Karki\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17.1 Background 250\u003c\/p\u003e \u003cp\u003e17.2 Pharmacology 251\u003c\/p\u003e \u003cp\u003e17.3 Structure?Activity Relationship (SAR) 253\u003c\/p\u003e \u003cp\u003e17.4 Pharmacokinetics and Drug Metabolism 256\u003c\/p\u003e \u003cp\u003e17.5 Efficacy and Safety 258\u003c\/p\u003e \u003cp\u003e17.6 Synthesis of Donepezil 259\u003c\/p\u003e \u003cp\u003e17.7 Synthesis of Rivastigmine 262\u003c\/p\u003e \u003cp\u003e17.8 Synthesis of Galantamine 265\u003c\/p\u003e \u003cp\u003e17.9 References 271\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 18. Aprepitant (Emend), A NK1 Receptor Antagonist for the Treatment of Post-chemotherapy Emesis 275\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJohn A. Lowe, III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e18.1 Background 275\u003c\/p\u003e \u003cp\u003e18.2 \u003ci\u003eIn Vitro\u003c\/i\u003e Pharmacology and Structure-Activity Relationships 279\u003c\/p\u003e \u003cp\u003e18.3 In Vivo Pharmacology 281\u003c\/p\u003e \u003cp\u003e18.4 Pharmacokinetics and Drug Metabolism 282\u003c\/p\u003e \u003cp\u003e18.5 Efficacy and Safety 282\u003c\/p\u003e \u003cp\u003e18.6 Syntheses 283\u003c\/p\u003e \u003cp\u003e18.7 References 289\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 19. Armodafinil (Nuvigil), A Psychostimulant for the Treatment of Narcolepsy 291\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eJi Zhang and Jason Crawford\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e19.1 Background 291\u003c\/p\u003e \u003cp\u003e19.2 Pharmacology 293\u003c\/p\u003e \u003cp\u003e19.3 Pharmacokinetics and Drug Metabolism 294\u003c\/p\u003e \u003cp\u003e19.4 Efficacy and Safety 295\u003c\/p\u003e \u003cp\u003e19.5 Synthesis 296\u003c\/p\u003e \u003cp\u003e19.6 References 303\u003c\/p\u003e \u003cp\u003e\u003cb\u003eV. Miscellaneous 307\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 20. Raloxifene (Evista), A Selective Estrogen Receptor Modulator (SERM) 309\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eMarta Piñeiro-Núñez\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e20.1 Background 309\u003c\/p\u003e \u003cp\u003e20.2 Mechanism of Action 313\u003c\/p\u003e \u003cp\u003e20.3 Pharmacokinetics and Drug Metabolism 313\u003c\/p\u003e \u003cp\u003e20.4 Efficacy and Safety 314\u003c\/p\u003e \u003cp\u003e20.5 Syntheses 315\u003c\/p\u003e \u003cp\u003e20.6 References 325\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 21. Latanoprost (Xalatan), A Prostanoid FP Agonist for Glaucoma 329\u003cbr\u003e\u003c\/b\u003e\u003ci\u003eSajiv K. Nair and Kevin E. Henegar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e21.1 Background 329\u003c\/p\u003e \u003cp\u003e21.2 Syntheses 331\u003c\/p\u003e \u003cp\u003e21.3 References 337\u003c\/p\u003e \u003cp\u003eIndex 339\u003c\/p\u003e\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\u003cp\u003e\u003cfont size=\"3\"\u003eSubject Areas: Chemistry [\u003ca title=\"See our other books on Chemistry\" href=\"https:\/\/freshlyprintedbooks.co.uk\/search?q=%22Chemistry%20%5BPN%5D%22\"\u003ePN\u003c\/a\u003e]\u003c\/font\u003e\u003c\/p\u003e\r\n\r\n\r\n\u003c\/font\u003e","brand":"Wiley","offers":[{"title":"Brand New","offer_id":52276360315160,"sku":"9780470525838","price":82.59,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0730\/2037\/5320\/files\/9780470525838.jpg?v=1781367103","url":"https:\/\/freshlyprintedbooks.co.uk\/products\/modern-drug-synthesis-hardback-9780470525838","provider":"Freshly Printed Books","version":"1.0","type":"link"}